View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 24, 2020updated 13 Feb 2020 10:30am

Coronavirus: Gilead, Purdue University explore potential treatments

At a time when multiple companies are announcing plans to develop vaccines for the new, deadly Wuhan coronavirus, Gilead Sciences is testing Ebola drug, while Purdue University researchers are working on oral treatments along with vaccines.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

At a time when multiple companies are announcing plans to develop vaccines for the new, deadly Wuhan coronavirus, Gilead Sciences is testing Ebola drug, while Purdue University researchers are working on oral treatments along with vaccines.

Gilead is exploring whether an investigational Ebola drug, remdesivir, can help address to combat the virus. Remdesivir is an experimental antiviral drug that was previously tested by the US National Institutes of Health (NIH) for Ebola and found to be ineffective.

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) director Dr Anthony Fauci said that in animal models, the drug demonstrated some ability to work against the coronavirus.

Coronavirus infections can lead to respiratory illnesses, including the deadly Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The virus is said to be similar to the SARS virus that emerged in 2003.

Gilead said that the company is in discussions with researchers and clinicians in the US and China regarding the ongoing outbreak and the potential use of its drug as an experimental therapy.

Meanwhile, Purdue University researchers working on the virus, intend to assess their drug candidates over the coming two weeks.

Molecules developed by the university scientists, Andrew Mesecar and Arun Ghosh, inhibit two coronavirus enzymes and prevent its replication. The discovered drug targets are said to be more than 95% similar to enzyme targets found on the SARS virus.

Researchers note that identified drugs may not be available to address the ongoing outbreak but they hope to make it accessible for future outbreaks.

Furthermore, the researchers said that the intermittent nature of the outbreaks and small market for drugs slow the development by companies.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU